GANX GAIN THERAPEUTICS INC US FDA Inspections 8-K Filing 2024 - Clinical Trial Approval Gain Therapeutics, Inc. announced that it has received approval to start a Phase 1b clinical trial in Australia for its drug GT-02287, aimed at treating Parkinson's disease, with enrollment expected to complete by spring 2025 and data anticipated by mid-2025.Get access to all SEC 8-K filings of the GAIN THERAPEUTICS INC